Liquid Biopsy may be a false hope

Commercial Liquid Biopsy for Early Detection: Ethical Realities & Specificity Defects

Report: Guardian Australia Analysis on Commercial Liquid Biopsies | Access Full Report via The Guardian

The Bottom Line

Direct-to-consumer advertising is currently marketing a $1,495 out-of-pocket liquid biopsy test (circulating tumour DNA) to Australian women for asymptomatic ovarian cancer. While early detection remains a critical goal, health leaders—including the Ovarian Cancer Research Foundation (OCRF)—warn that commercially offering this unapproved TGA test carries major ethical concerns and severe diagnostic limitations. With a sensitivity of ~78% and a specificity of ~94%, the test simultaneously misses a quarter of true cancers while generating thousands of false alarms in healthy women.

The Two-Way Diagnostic Flaw

┌─────────────────────────────────────────────────────────────────────────┐
│                          COMMERCIAL TEST PROFILE                        │
├───────────────────────────────┬─────────────────────────────────────────┤
│ Sensitivity Defect (~78%)     │ Specificity Defect (~94%)               │
├───────────────────────────────┼─────────────────────────────────────────┤
│ • Misses ~22% of true cancers │ • 6% false positive rate in healthy cohort│
│ • Creates false reassurance   │ • Triggers psychological trauma         │
│ • Delays legitimate care      │ • Leads to invasive, unnecessary workups│
└───────────────────────────────┴─────────────────────────────────────────┘

  • The Specificity Defect (False Positive Cascade): A 94% specificity sounds high, but in a general or asymptomatic population where disease prevalence is low, a 6% false-positive rate is catastrophic. Public health modelling demonstrates that if tested across a broad cohort of 100,000 women, roughly 6,000 healthy women will incorrectly test positive.

  • Downstream Harm & Resource Strain: Those 6,000 healthy women—having already paid $1,495 out-of-pocket—are thrust into severe anxiety and forced into the Australian health system for unnecessary CT scans, pelvic ultrasounds, specialist visits, or invasive surgery to rule out non-existent disease.

  • The Sensitivity Defect (False Negatives): With a 78.2% sensitivity, more than 1 in 5 women with actual ovarian cancer will receive a negative result, providing false reassurance that may cause them to ignore emerging clinical symptoms.

  • Regulatory & Data Reality: The test lacks TGA approval for screening, is not endorsed by clinical guidelines, and relies on very limited peer-reviewed data.

Expert Reality Check: "The BCAL test may have some value but doesn't yet meet the threshold for sensitivity and specificity... There is no robust evidence demonstrating blood-based early detection screening tests improve health outcomes." — OCRF / University of Sydney Public Health

What OCA Support Nurses Need to Know

  • Explaining the Specificity Trap: Support nurses can help patients understand that "94% specific" does not mean a positive result is 94% accurate. In asymptomatic women, a positive result is far more likely to be a false alarm than real cancer.

  • Grounding Anxious Callers: Nurses fielding inquiries about these direct-to-consumer ads should confirm that this test is not TGA-approved for screening and cannot replace standard GP clinical evaluations or validated genetic testing pathways.

  • Advocating for Symptom-Based Evaluation: Remind patients that if they experience persistent symptoms (bloating, pelvic pain, feeling full quickly, urinary frequency), a negative commercial blood test must never be used to rule out disease—immediate clinical workup remains essential.

Quick Tags:

#LiquidBiopsy #EarlyDetection #Bioethics #HealthEquity #DirectToConsumer #PatientAdvocacy

Comments

Post a Comment

Popular posts from this blog

An impossible dream?

Image
Reducing ovarian cancer mortality through screening: an impossible dream? https://tinyurl.com/4524jh8f The history of screening tests for ovarian cancer is not good. Two huge trials; the UKCTOCS with  more than 200,000 recruits over 20 years and the PLCO trial with more than 3 million pathology samples  sho wed no benefit in terms of survival from ovarian cancer. This article addresses the stages of ovarian cancer using  an alternative approach called the clinical continuum,  which divides cancer into 3 phases ,  no disease, pre-clinical  (detectable disease) , and  clinical (overt cancer). Obviously for a screening test to be effective ,   cancer needs to be detected before the clinical  phase. However, ovarian cancer is unlike other cancer in that the precursor occurs in the fallopian tube and the re is an argument to say that ,  by the time ovarian cancer has occurred ,  it is always advanced and metastatic .   T his time in...
Read more

It’s not just your genotype

Image
Exploring causal relationships between brain imaging-derived phenotypes and ovarian cancer risk: a bidirectional Mendelian randomization https://tinyurl.com/yhfkpwyb One of the perplexing aspects of ovarian cancer is why there is individual variation between those who do have cancer and those who don’t . It would be expected that women with high risk due to genetic mutation such as BR CA2 would all eventually succumb to breast or ovarian cancer. However, many (about 2 0%) , do not. This study suggests that brain structure and function may be part of the reason this is so. Magnetic Resonance Imaging (MRI) is able in a non-invasive way to identify different brain shapes and anatomy . Using data from the UK Biobank study it has bee n possible to identify 12 distinct varieties of brain anatomy which have an influence on ovarian cancer. Further investigation suggested distinct areas of brain cortex variation, with the right medial cortex being protective , and the right pre-cen...
Read more

Sugar doesn’t feed cancer

Image
Revisiting the Warburg-Based “Sugar Feeds Cancer” Hypothesis: A Critical Appraisal of Epidemiological, Experimental and Mechanistic Evidence https://tinyurl.com/3v2tysdt Many clinical care professionals receive queries from cancer patients about whether they should modify their diet to red u ce consumed sugar. This concern is based on a misunde r standing of some basic medical research known as the Warbur g effect. Research from 1956 show ed that cancer cells alter their metaboli sm to enable increased glucose uptake and increase energy production. A misunderstanding of this effect has led to incorrect dietary advice to cancer patients suggesting sugar restriction may be benefi cial. As a result, malnutrition , which is already a s i gnificant cause of morbidity for cancer patients , can be exacerbated . No hard evidence that low sugar diets alter survival exists. Some anecdotal reports suggest a slight correlation with risk. This study is a n appraisal of all credible re...
Read more